Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Donald Bodenner to Treatment Outcome

This is a "connection" page, showing publications Donald Bodenner has written about Treatment Outcome.

 
Connection Strength
  
 
 
0.208
  
  1. Middleton L, Stack BC, Riggs AT, Bodenner DL. Vitamin D deficiency: a simple algorithm employing weekly administration of 50,000 IU of vitamin D. Am J Otolaryngol. 2014 Mar-Apr; 35(2):85-8.
    View in: PubMed
    Score: 0.055
  2. Frank RW, Middleton L, Stack BC, Spencer HJ, Riggs AT, Bodenner DL. Conservative management of thyroglobulin-positive, nonlocalizable thyroid carcinoma. Head Neck. 2014 Feb; 36(2):155-7.
    View in: PubMed
    Score: 0.053
  3. Hamid Z, Riggs A, Spencer T, Redman C, Bodenner D. Vitamin D deficiency in residents of academic long-term care facilities despite having been prescribed vitamin D. J Am Med Dir Assoc. 2007 Feb; 8(2):71-5.
    View in: PubMed
    Score: 0.034
  4. Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, McCaffrey J, Newbold K, Allison R, Martins RG, Licitra LF, Shah MH, Bodenner D, Elisei R, Burmeister L, Funahashi Y, Ren M, O'Brien JP, Sherman SI. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clin Cancer Res. 2016 Jan 01; 22(1):44-53.
    View in: PubMed
    Score: 0.015
  5. Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, Andresen C, O'Brien JP, Ren M, Funahashi Y, Allison R, Elisei R, Newbold K, Licitra LF, Sherman SI, Ball DW. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer. 2015 Aug 15; 121(16):2749-56.
    View in: PubMed
    Score: 0.015
  6. Rutledge J, Siegel E, Belcher R, Bodenner D, Stack BC. Barriers to same-day discharge of patients undergoing total and completion thyroidectomy. Otolaryngol Head Neck Surg. 2014 May; 150(5):770-4.
    View in: PubMed
    Score: 0.014
  7. Francis CL, Nalley C, Fan C, Bodenner D, Stack BC. 18F-fluorodeoxyglucose and 131I radioguided surgical management of thyroid cancer. Otolaryngol Head Neck Surg. 2012 Jan; 146(1):26-32.
    View in: PubMed
    Score: 0.012
  8. Nalley C, Wiebeck K, Bartel TB, Bodenner D, Stack BC. Intraoperative radiation exposure with the use of (18)F-FDG-guided thyroid cancer surgery. Otolaryngol Head Neck Surg. 2010 Feb; 142(2):281-3.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.